Full Press Release Details
Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
YORK and VANCOUVER, British Columbia, July 14, 2021- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast
cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The
Phase I/IIa combination study is designed to evaluate BriaCell's lead candidate, Bria-IMT , with Incyte's checkpoint
inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.
BriaCell and Incyte clinical program is a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel
clinical candidates. Under the agreement, Incyte is providing compounds from its development portfolio, including retifanlimab, an anti-PD-1
monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with Bria-IMT , in advanced breast cancer
and Incyte had previously treated two patients under this Phase I/IIa combination study subsequent to the corporate collaboration commencement
in April 2019. Some of those patients were included in BriaCell's recent survival data announcement.
With funding now secured, BriaCell has once again opened this collaborative study to enrollment.
are aligned with our clinical collaboration partners at Incyte in placing value on innovation and look forward to further developing
novel therapeutics for advanced breast cancer patients together," stated Dr. Bill Williams, BriaCell's President and CEO.
"Our preliminary data indicates that this novel combination has the potential to be a safe and effective treatment for advanced
breast cancer patients who have few to no other treatment options."
BriaCell Therapeutics Corp.
is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading
"Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks
and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities
and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty
to update such information except as required under applicable law.
TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.